The human PC346 xenograft and cell line panel: A model system for prostate cancer progression

European Urology

Volumn 49, Issue 2, 2006, Pages 245-257

  Marques, Rute B ^a   Van Weerden, Wytske M ^a   Erkens Schulze, Sigrun ^a   De Ridder, Corrina M ^a   Bangma, Chris H ^a   Trapman, Jan ^a   Jenster, Guido ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Androgen receptor; Antiandrogen; Cell line; Hormone resistance; Prostate carcinoma; Xenograft

Indexed keywords

ANDROGEN RECEPTOR;

CANCER CELL CULTURE; CANCER GROWTH; HISTOPATHOLOGY; HORMONE RESPONSE; HUMAN; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 32044451769     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.035     Document Type: Review

References (69)

1. N.M. Navone, C.J. Logothetis, A.C. von Eschenbach, and P. Troncoso Model systems of prostate cancer: uses and limitations Cancer Metastasis Rev 17 4 1998 361 371
2. A. Van Bokhoven, M. Varella-Garcia, C. Korch, W.U. Johannes, E.E. Smith, and H.L. Miller Molecular characterization of human prostate carcinoma cell lines Prostate 57 3 2003 205 225
3. W.M. van Weerden, and J.C. Romijn Use of nude mouse xenograft models in prostate cancer research Prostate 43 4 2000 263 271
4. Y. Wang, M.P. Revelo, D. Sudilovsky, M. Cao, W.G. Chen, and L. Goetz Development and characterization of efficient xenograft models for benign and malignant human prostate tissue Prostate 64 2 2005 149 159
5. W. Hoehn, M. Wagner, J.F. Riemann, P. Hermanek, E. Williams, and R. Walther Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice Prostate 5 4 1984 445 452
6. W. Hoehn, F.H. Schroeder, J.F. Reimann, A.C. Joebsis, and P. Hermanek Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82) Prostate 1 1 1980 95 104
7. W.M. van Weerden, C.M. de Ridder, C.L. Verdaasdonk, J.C. Romijn, T.H. van der Kwast, and F.H. Schroder Development of seven new human prostate tumor xenograft models and their histopathological characterization Am J Pathol 149 3 1996 1055 1062
8. T.G. Pretlow, S.R. Wolman, M.A. Micale, R.J. Pelley, E.D. Kursh, and M.I. Resnick Xenografts of primary human prostatic carcinoma J Natl Cancer Inst 85 5 1993 394 398
9. M. Nagabhushan, C.M. Miller, T.P. Pretlow, J.M. Giaconia, N.L. Edgehouse, and S. Schwartz CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar Cancer Res 56 13 1996 3042 3046
10. W.J. Ellis, R.L. Vessella, K.R. Buhler, F. Bladou, L.D. True, and S.A. Bigler Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23 Clin Cancer Res 2 6 1996 1039 1048
11. Y.G. Lee, S. Korenchuk, J. Lehr, S. Whitney, R. Vessela, and K.J. Pienta Establishment and characterization of a new human prostatic cancer cell line: DuCaP In Vivo 15 2 2001 157 162
12. K.R. Buhler, J.E. Quinn, S.C. Whitney, D.W. Lin, W.J. Ellis, and E. Corey Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations J Urol 161 4S 1999 58
13. M.J. Linja, K.J. Savinainen, O.R. Saramaki, T.L. Tammela, R.L. Vessella, and T. Visakorpi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 9 2001 3550 3555
14. S. Laitinen, R. Karhu, C.L. Sawyers, R.L. Vessella, and T. Visakorpi Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization Genes Chromosomes Cancer 35 1 2002 66 73
15. L.D. True, K. Buhler, J. Quinn, E. Williams, P.S. Nelson, and N. Clegg A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49 Am J Pathol 161 2 2002 705 715
16. K.A. Klein, R.E. Reiter, J. Redula, H. Moradi, X.L. Zhu, and A.R. Brothman Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice Nat Med 3 4 1997 402 408
17. N. Craft, C. Chhor, C. Tran, A. Belldegrun, J. DeKernion, and O.N. Witte Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process Cancer Res 59 19 1999 5030 5036
18. M.E. Harper, L. Goddard, C. Smith, and R.I. Nicholson Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines Prostate 58 1 2004 13 22
19. D.R. McCulloch, K. Opeskin, E.W. Thompson, and E.D. Williams BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis Prostate 65 1 2005 35 43
20. M.E. Kaighn, K.S. Narayan, Y. Ohnuki, J.F. Lechner, and L.W. Jones Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest Urol 17 1 1979 16 23
21. K.R. Stone, D.D. Mickey, H. Wunderli, G.H. Mickey, and D.F. Paulson Isolation of a human prostate carcinoma cell line (DU 145) Int J Cancer 21 3 1978 274 281
22. J.S. Horoszewicz, S.S. Leong, T.M. Chu, Z.L. Wajsman, M. Friedman, and L. Papsidero The LNCaP cell line - a new model for studies on human prostatic carcinoma Prog Clin Biol Res 37 1980 115 132
23. R.D. Williams Human urologic cancer cell lines Invest Urol 17 5 1980 359 363
24. H.B. Grossman, G. Wedemeyer, L. Ren, and T.E. Carey UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma Cancer Res 44 9 1984 4111 4117
25. H.Y. Zhau, S.M. Chang, B.Q. Chen, Y. Wang, H. Zhang, and C. Kao Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93 26 1996 15152 15157
26. N.M. Navone, M. Olive, M. Ozen, R. Davis, P. Troncoso, and S.M. Tu Establishment of two human prostate cancer cell lines derived from a single bone metastasis Clin Cancer Res 3 12 Pt 1 1997 2493 2500
27. R.M. Sramkoski, T.G. Pretlow 2nd, J.M. Giaconia, T.P. Pretlow, S. Schwartz, and M.S. Sy A new human prostate carcinoma cell line, 22Rv1 In Vitro Cell Dev Biol Anim 35 7 1999 403 409
28. C.J. Kim, R. Kushima, Y. Okada, and A. Seto Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome Prostate 42 4 2000 287 294
29. C.W. Gregory, R.T. Johnson Jr., J.L. Mohler, F.S. French, and E.M. Wilson Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 7 2001 2892 2898
30. S. Korenchuk, J.E. Lehr, L. McLean, Y.G. Lee, S. Whitney, and R. Vessella VCaP, a cell-based model system of human prostate cancer In Vivo 15 2 2001 163 168
31. S. Koochekpour, Y.J. Zhuang, R. Beroukhim, C.L. Hsieh, M.D. Hofer, and H.E. Zhau Amplification and overexpression of prosaposin in prostate cancer Genes Chromosomes Cancer 44 4 2005 351 364
32. G.J. van Steenbrugge, M. Groen, F.H. de Jong, and F.H. Schroeder The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles Prostate 5 6 1984 639 647
33. G.H. Heppner Tumor heterogeneity Cancer Res 44 6 1984 2259 2265
34. J.T. Isaacs, and D.S. Coffey Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 12 Pt 1 1981 5070 5075
35. C.A. Macintosh, M. Stower, N. Reid, and N.J. Maitland Precise microdissection of human prostate cancers reveals genotypic heterogeneity Cancer Res 58 1 1998 23 28
36. L. Cheng, S.Y. Song, T.G. Pretlow, F.W. Abdul-Karim, H.J. Kung, and D.V. Dawson Evidence of independent origin of multiple tumors from patients with prostate cancer J Natl Cancer Inst 90 3 1998 233 237
37. D.G. Bostwick, A. Shan, J. Qian, M. Darson, N.J. Maihle, and R.B. Jenkins Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma Cancer 83 9 1998 1995 2002
38. A. So, M. Gleave, A. Hurtado-Col, and C. Nelson Mechanisms of the development of androgen independence in prostate cancer World J Urol 23 1 2005 1 9
39. R.B. Marques, S. Erkens-Schulze, C.M. de Ridder, K.G. Hermans, K. Waltering, and T. Visakorpi Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment Int J Cancer 117 2 2005 221 229
40. E.P. Gelmann Molecular biology of the androgen receptor J Clin Oncol 20 13 2002 3001 3015
41. T.H. van der Kwast, J. Schalken, J.A. Ruizeveld de Winter, C.C. van Vroonhoven, E. Mulder, and W. Boersma Androgen receptors in endocrine-therapy- resistant human prostate cancer Int J Cancer 48 2 1991 189 193
42. J.A. Ruizeveld de Winter, P.J. Janssen, H.M. Sleddens, M.C. Verleun-Mooijman, J. Trapman, and A.O. Brinkmann Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 144 4 1994 735 746
43. G. Jenster The role of the androgen receptor in the development and progression of prostate cancer Semin Oncol 26 4 1999 407 421
44. Z. Culig, H. Steiner, G. Bartsch, and A. Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr Relat Cancer 12 2 2005 229 244
45. C.W. Gregory, B. He, R.T. Johnson, O.H. Ford, J.L. Mohler, and F.S. French A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res 61 11 2001 4315 4319
46. S.M. Henshall, D.I. Quinn, C.S. Lee, D.R. Head, D. Golovsky, and P.C. Brenner Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer Cancer Res 61 2 2001 423 427
47. P. Koivisto, J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, and J. Isola Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 57 2 1997 314 319
48. R.S. Brown, J. Edwards, A. Dogan, H. Payne, S.J. Harland, and J.M. Bartlett Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer J Pathol 198 2 2002 237 244
49. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogen therapy Nat Med 10 1 2004 33 39
50. Z.Q. Huang, J. Li, and J. Wong AR possesses an intrinsic hormone-independent transcriptional activity Mol Endocrinol 16 5 2002 924 937
51. G. Han, G. Buchanan, M. Ittmann, J.M. Harris, X. Yu, and F.J. Demayo Mutation of the androgen receptor causes oncogenic transformation of the prostate Proc Natl Acad Sci USA 102 4 2005 1151 1156
52. M.E. Taplin, B. Rajeshkumar, S. Halabi, C.P. Werner, B.A. Woda, and J. Picus Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 J Clin Oncol 21 14 2003 2673 2678
53. Z. Culig, A. Hobisch, A. Hittmair, M.V. Cronauer, C. Radmayr, and G. Bartsch Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy Drugs Aging 10 1 1997 50 58
54. J. Veldscholte, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, C. Berrevoets, and E. Claassen A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 173 2 1990 534 540
55. J.P. Gaddipati, D.G. McLeod, H.B. Heidenberg, I.A. Sesterhenn, M.J. Finger, and J.W. Moul Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res 54 11 1994 2861 2864
56. H. Suzuki, K. Akakura, A. Komiya, S. Aida, S. Akimoto, and J. Shimazaki Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome Prostate 29 3 1996 153 158
57. G. Buchanan, N.M. Greenberg, H.I. Scher, J.M. Harris, V.R. Marshall, and W.D. Tilley Collocation of androgen receptor gene mutations in prostate cancer Clin Cancer Res 7 5 2001 1273 1281
58. P.J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin Chem 44 4 1998 705 723
59. S.D. Catz, and J.L. Johnson BCL-2 in prostate cancer: a minireview Apoptosis 8 1 2003 29 37
60. R.J. Vlietstra, D.C. van Alewijk, K.G. Hermans, G.J. van Steenbrugge, and J. Trapman Frequent inactivation of PTEN in prostate cancer cell lines and xenografts Cancer Res 58 13 1998 2720 2723
61. S. Gurumurthy, K.M. Vasudevan, and V.M. Rangnekar Regulation of apoptosis in prostate cancer Cancer Metastasis Rev 20 3-4 2001 225 243
62. W.M. van Weerden, A. van Kreuningen, N.M. Elissen, M. Vermeij, F.H. de Jong, and G.J. van Steenbrugge Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice Prostate 23 2 1993 149 164
63. J. Tan, Y. Sharief, K.G. Hamil, C.W. Gregory, D.Y. Zang, and M. Sar Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells Mol Endocrinol 11 4 1997 450 459
64. A. Chlenski, K. Nakashiro, K.V. Ketels, G.I. Korovaitseva, and R. Oyasu Androgen receptor expression in androgen-independent prostate cancer cell lines Prostate 47 1 2001 66 75
65. J. Veldscholte, C.A. Berrevoets, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, and J. Trapman The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J Steroid Biochem Mol Biol 41 3-8 1992 665 669
66. A. van Bokhoven, A. Caires, M.D. Maria, A.P. Schulte, M.S. Lucia, and S.K. Nordeen Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines Prostate 57 3 2003 226 244
67. G.G. Kuiper, P.E. de Ruiter, J. Trapman, W.J. Boersma, J.A. Grootegoed, and A.O. Brinkmann Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor Biochem J 291 Pt 1 1993 95 101
68. G. Jenster, P.E. de Ruiter, H.A. van der Korput, G.G. Kuiper, J. Trapman, and A.O. Brinkmann Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites Biochemistry 33 47 1994 14064 14072
69. N.D. Zegers, E. Claassen, C. Neelen, E. Mulder, J.H. van Laar, and M.M. Voorhorst Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy Biochim Biophys Acta 1073 1 1991 23 32